14 July 2023: Aker BioMarine ASA ("Aker BioMarine" or "the company") reports
revenues of USD 88.6 million, up 21% from USD 73.4 million last year. Adjusted
EBITDA was USD 21.5 million, flat from the second quarter of 2022. 

Highlights second quarter:
- Continued year-over-year revenue growth for the Group
- Adjusted EBITDA of USD 21.5 million (USD 21.4 million) 
- Good harvesting operations, tracking on par with last year
- Qrill Aqua and Superba delivers good volume growth, margins impacted by
onboarding of new client, regional fuel price spread and temporary no production
in Houston
- Brands delivered 9% YoY revenue growth 
- Health claim for Superba approved in the South Korean market - preparing for
re-launch
- Announced intention to change Group financial reporting and legal entity
structure
- Delivery of the USV from Maritime Robotics after quarter end
- Protein factory in Ski, Norway completed on time and budget

"Aker BioMarine continues the year-over-year revenue growth, including good
performance in our harvesting operations. Although sales have increased, margins
declined compared to last year due to factors such as higher fuel costs,
customer and product mix, and low production in our Houston factory. However, we
view many of these factors as temporary and remain optimistic about the overall
progress of our business", said Matts Johansen, CEO of Aker BioMarine.

Outlook
For third quarter 2023 we expect Qrill Aqua and Superba revenues, as well as
Brands revenues to be above same quarter last year. 

We expect long-term average annual sales growth for Aker BioMarine to be in line
with earlier communicated ambitions at around 15%.

At 09:00 CET today, the management hosts a webcast. Following the presentation,
there will be a Q&A session, where written questions can be submitted to
ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that
is available at www.akerbiomarine.com/investor. 

A replay of the presentation and Q&A session material will be made available
soon after the presentation at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.